Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone as Bupivacaine Adjuvant in ESPB for Laparoscopic Cholecystectomy
NCT05105997Phase 2
Key facts
- Status
- Unknown
- Start
- Dec 2022
- Primary completion
- Jul 2023
- Sponsor
- Assiut University
- Modality
- Orthosteric Ligands
- Drugs
- dexamethasone
- Conditions
- postoperative pain
01
Overview
Phase 2, randomised, double-blind trial of dexamethasone in postoperative pain (2 arms), sponsored by Assiut University. Primary endpoint: Intensity of postoperative pain at 24 hours. Status: unknown.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Dexamethasone + Bupivacaine
Bupivacaine + Saline
03
Who it enrols
Patients aged 18-65 undergoing elective laparoscopic cholecystectomy with ASA status I-II, excluding those with contraindications to regional block, pregnancy, BMI > 35, or chronic opioid use.
04
Endpoints
Primary
Intensity of postoperative pain
Beyond the preview
Go deeper on NCT05105997.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105997.